BioLineRx (BLRX) Reports Partial Results Data from Open-Label Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment
Tweet Send to a Friend
BioLineRx Ltd. (NASDAQ: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, reported partial results data from its open-label ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
